“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Chugai Pharma USA


Chugai Pharma USA products


A

  • Alecensa® — alectinib
    Indication: ALK-positive, advanced or recurrent non–small cell lung cancer; also used as adjuvant therapy

  • Actemra® — tocilizumab
    Indications: rheumatoid arthritis, adult Still’s disease, Castleman’s disease, and COVID-19 pneumonia requiring oxygen support

E

  • Enspryng® — satralizumab
    Indication: neuromyelitis optica spectrum disorder (NMOSD)

  • Evrysdi® — risdiplam
    Indication: treatment of spinal muscular atrophy

H

  • Hemlibra® — emicizumab
    Indication: prophylaxis for hemophilia A with or without factor VIII inhibitors

O

  • **Ongoing Oncology Biosimilars**
    (e.g., Avastin® /bevacizumab, Herceptin® /trastuzumab, Kadcyla® /trastuzumab emtansine, Perjeta® /pertuzumab, Tecentriq® /atezolizumab, Lunsumio® /mosunetuzumab, Polivy® /polatuzumab vedotin, Phesgo® (combo) )
    Indications: various cancer types, including breast, colorectal, lung cancer, and lymphoma

T

  • Tamiflu® — oseltamivir
    Indication: treatment of influenza




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)